

Klemens Budde

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6190154/publications.pdf>

Version: 2024-02-01

566
papers

25,224
citations

8181

76
h-index

11607

135
g-index

622
all docs

622
docs citations

622
times ranked

19433
citing authors

#	ARTICLE	IF	CITATIONS
1	Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. <i>Pediatric Neurology</i> , 2013, 49, 243-254.	2.1	1,185
2	Angiotensin II Type 1 Receptor Activating Antibodies in Renal-Allograft Rejection. <i>New England Journal of Medicine</i> , 2005, 352, 558-569.	27.0	760
3	Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2013, 381, 817-824.	13.7	712
4	Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. <i>Pediatric Neurology</i> , 2013, 49, 255-265.	2.1	693
5	Results of an International, Randomized Trial Comparing Glucose Metabolism Disorders and Outcome with Cyclosporine Versus Tacrolimus. <i>American Journal of Transplantation</i> , 2007, 7, 1506-1514.	4.7	530
6	Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease. <i>New England Journal of Medicine</i> , 2010, 363, 830-840.	27.0	517
7	Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2019, 393, 1937-1947.	13.7	408
8	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 261-307.	2.0	374
9	Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. <i>Lancet, The</i> , 2011, 377, 837-847.	13.7	326
10	Anti-Human Leukocyte Antigen and Donor-Specific Antibodies Detected by Luminex Posttransplant Serve as Biomarkers for Chronic Rejection of Renal Allografts. <i>Transplantation</i> , 2009, 87, 1505-1513.	1.0	313
11	CC chemokine receptor 5 and renal-transplant survival. <i>Lancet, The</i> , 2001, 357, 1758-1761.	13.7	283
12	First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 1073-1083.	6.1	257
13	Enteric-Coated Mycophenolate Sodium can be Safely Administered in Maintenance Renal Transplant Patients: Results of a 1-Year Study. <i>American Journal of Transplantation</i> , 2004, 4, 237-243.	4.7	238
14	Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial. <i>Transplantation</i> , 2008, 86, 1043-1051.	1.0	238
15	Biomarkers in acute kidney injury – pathophysiological basis and clinical performance. <i>Acta Physiologica</i> , 2017, 219, 556-574.	3.8	238
16	Donor-Specific HLA Antibodies in a Cohort Comparing Everolimus With Cyclosporine After Kidney Transplantation. <i>American Journal of Transplantation</i> , 2012, 12, 1192-1198.	4.7	231
17	Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. <i>Pediatric Neurology</i> , 2021, 123, 50-66.	2.1	230
18	Predictors of Success in Conversion from Calcineurin Inhibitor to Sirolimus in Chronic Allograft Dysfunction. <i>American Journal of Transplantation</i> , 2004, 4, 1869-1875.	4.7	229

#	ARTICLE	IF	CITATIONS
19	Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. <i>Science Immunology</i> , 2021, 6, eabj1031.	11.9	223
20	Corticosteroid-Free Immunosuppression with Tacrolimus, Mycophenolate Mofetil, and Daclizumab Induction in Renal Transplantation. <i>Transplantation</i> , 2005, 79, 807-814.	1.0	217
21	Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	212
22	Three-Year Efficacy and Safety Results from a Study of Everolimus Versus Mycophenolate Mofetil in de novo Renal Transplant Patients. <i>American Journal of Transplantation</i> , 2005, 5, 2521-2530.	4.7	208
23	Neutrophil gelatinase-associated lipocalin: pathophysiology and clinical applications. <i>Acta Physiologica</i> , 2013, 207, 663-672.	3.8	206
24	Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy. <i>Journal of Clinical Investigation</i> , 2016, 126, 2519-2532.	8.2	181
25	Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, iv15-iv25.	0.7	180
26	Interleukin 6 is an autocrine growth factor for mesangial cells. <i>Kidney International</i> , 1990, 38, 249-257.	5.2	179
27	Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantation Society Working Group. <i>Transplantation</i> , 2020, 104, 911-922.	1.0	172
28	Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). <i>Arthritis Research and Therapy</i> , 2011, 13, R75.	3.5	170
29	Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 819-822.	0.7	159
30	Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2003, 55, 203-211.	2.4	156
31	Diets and enteral supplements for improving outcomes in chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2011, 7, 369-384.	9.6	147
32	Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 65, 251-261.	4.7	146
33	FTY720 versus MMF with Cyclosporine in de novo Renal Transplantation: A 1-Year, Randomized Controlled Trial in Europe and Australasia. <i>American Journal of Transplantation</i> , 2006, 6, 2912-2921.	4.7	145
34	Randomized Phase 2b Trial of Tofacitinib (CP-690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year. <i>American Journal of Transplantation</i> , 2012, 12, 2446-2456.	4.7	140
35	Pre-Transplant Inosine Monophosphate Dehydrogenase Activity is Associated with Clinical Outcome After Renal Transplantation. <i>American Journal of Transplantation</i> , 2004, 4, 2045-2051.	4.7	138
36	Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study. <i>PLoS ONE</i> , 2017, 12, e0180939.	2.5	128

#	ARTICLE	IF	CITATIONS
37	The pharmacokinetics of pioglitazone in patients with impaired renal function. <i>British Journal of Clinical Pharmacology</i> , 2003, 55, 368-374.	2.4	125
38	Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study. <i>Transplant International</i> , 2014, 27, 77-86.	1.6	125
39	Epilepsy in tuberous sclerosis complex: Findings from the TOSCA Study. <i>Epilepsia Open</i> , 2019, 4, 73-84.	2.4	125
40	Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 330-340.	4.7	124
41	Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioliomyomatosis: extension of a randomized controlled trial. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 111-119.	0.7	120
42	Donor-Recipient Matching Based on Predicted Indirectly Recognizable HLA Epitopes Independently Predicts the Incidence of De Novo Donor-Specific HLA Antibodies Following Renal Transplantation. <i>American Journal of Transplantation</i> , 2017, 17, 3076-3086.	4.7	117
43	Motivations, Challenges, and Attitudes to Self-management in Kidney Transplant Recipients: A Systematic Review of Qualitative Studies. <i>American Journal of Kidney Diseases</i> , 2016, 67, 461-478.	1.9	116
44	UGT1A9 -275T>A/-2152C>T Polymorphisms Correlate With Low MPA Exposure and Acute Rejection in MMF/Tacrolimus-Treated Kidney Transplant Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 86, 319-327.	4.7	112
45	Age-matching in renal transplantation. <i>Nephrology Dialysis Transplantation</i> , 2000, 15, 696-700.	0.7	111
46	Old-for-Old Kidney Allocation Allows Successful Expansion of the Donor and Recipient Pool. <i>American Journal of Transplantation</i> , 2003, 3, 1434-1439.	4.7	111
47	CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 339-348.	1.5	110
48	Five-Year Outcomes in Kidney Transplant Patients Converted From Cyclosporine to Everolimus: The Randomized ZEUS Study. <i>American Journal of Transplantation</i> , 2015, 15, 119-128.	4.7	109
49	Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1246-1251.	0.7	108
50	The need for minimization strategies: current problems of immunosuppression. <i>Transplant International</i> , 2015, 28, 891-900.	1.6	104
51	Pharmacokinetic and Pharmacodynamic Comparison of Enteric-Coated Mycophenolate Sodium and Mycophenolate Mofetil in Maintenance Renal Transplant Patients. <i>American Journal of Transplantation</i> , 2007, 7, 888-898.	4.7	103
52	After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. <i>Kidney International</i> , 2020, 98, 1044-1052.	5.2	103
53	Therapeutic Drug Monitoring of Everolimus. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 143-169.	2.0	102
54	A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 708-722.	6.1	101

#	ARTICLE	IF	CITATIONS
55	Novel views on new-onset diabetes after transplantation: development, prevention and treatment. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 550-566.	0.7	100
56	Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk. <i>Transplant International</i> , 2010, 23, 1191-1204.	1.6	98
57	Quality of Life of Living Kidney Donors in Germany: A Survey with the Validated Short Form-36 and Giessen Subjective Complaints List-24 Questionnaires. <i>Transplantation</i> , 2004, 78, 864-872.	1.0	97
58	Pharmacodynamics of Single Doses of the Novel Immunosuppressant FTY720 in Stable Renal Transplant Patients. <i>American Journal of Transplantation</i> , 2003, 3, 846-854.	4.7	96
59	Novel Once-Daily Extended-Release Tacrolimus (LCPT) Versus Twice-Daily Tacrolimus in De Novo Kidney Transplants: One-Year Results of Phase III, Double-Blind, Randomized Trial. <i>American Journal of Transplantation</i> , 2014, 14, 2796-2806.	4.7	96
60	FTY720 (fingolimod) in renal transplantation. <i>Clinical Transplantation</i> , 2006, 20, 17-24.	1.6	92
61	Tuberous Sclerosis Complex-associated Angiomyolipomas: Focus on mTOR Inhibition. <i>American Journal of Kidney Diseases</i> , 2012, 59, 276-283.	1.9	91
62	Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. <i>Kidney International</i> , 2014, 86, 1244-1252.	5.2	91
63	A systematic approach to managing pregnant dialysis patients—the importance of an intensified haemodiafiltration protocol. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 2537-2542.	0.7	90
64	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 150-200.	2.0	89
65	Testosterone Concentrations and Sirolimus in Male Renal Transplant Patients. <i>American Journal of Transplantation</i> , 2004, 4, 130-131.	4.7	87
66	European Association of Urology Guidelines on Renal Transplantation: Update 2018. <i>European Urology Focus</i> , 2018, 4, 208-215.	3.1	85
67	Review of the immunosuppressant enteric-coated mycophenolate sodium. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 1333-1345.	1.8	84
68	Toward Establishing Core Outcome Domains For Trials in Kidney Transplantation. <i>Transplantation</i> , 2017, 101, 1887-1896.	1.0	83
69	Conversion From Twice-Daily Tacrolimus to Once-Daily Extended Release Tacrolimus (LCPT): The Phase III Randomized MELT Trial. <i>American Journal of Transplantation</i> , 2013, 13, 760-769.	4.7	82
70	B and T Cell Responses after a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 3027-3033.	6.1	82
71	Impact of POR*28 on the Pharmacokinetics of Tacrolimus and Cyclosporine A in Renal Transplant Patients. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 71-79.	2.0	81
72	Calcium Channel Blockade and Preservation of Renal Graft Function in Cyclosporine-Treated Recipients: A Prospective Randomized Placebo-Controlled 2-Year Study. <i>Transplantation</i> , 2004, 78, 1204-1211.	1.0	79

#	ARTICLE	IF	CITATIONS
73	Population Pharmacokinetics of Mycophenolic Acid. <i>Clinical Pharmacokinetics</i> , 2008, 47, 827-838.	3.5	79
74	Long-term risks of kidney living donation: review and position paper by the ERA-EDTA DESCARTES working group. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 216-223.	0.7	79
75	De novo hemolytic uremic syndrome postrenal transplant after cytomegalovirus infection. <i>American Journal of Kidney Diseases</i> , 1999, 34, 556-559.	1.9	78
76	Non-radioactive determination of inosine 5â€²-monophosphate dehydro-genase (IMPDH) in peripheral mononuclear cells. <i>Clinical Biochemistry</i> , 2001, 34, 543-549.	1.9	78
77	Sotrastaurin, a Novel Small Molecule Inhibiting Protein Kinase C: First Clinical Results in Renal-Transplant Recipients. <i>American Journal of Transplantation</i> , 2010, 10, 571-581.	4.7	78
78	Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation. <i>Therapeutic Drug Monitoring</i> , 2016, 38, S1-S20.	2.0	78
79	Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial. <i>American Journal of Kidney Diseases</i> , 2016, 67, 648-659.	1.9	78
80	Complex HBV populations with mutations in core promoter, C gene, and pre-S region are associated with development of cirrhosis in long-term renal transplant recipients. <i>Hepatology</i> , 2002, 35, 466-477.	7.3	77
81	Conversion From Cyclosporine to Everolimus at 4.5 Months Posttransplant: 3-Year Results From the Randomized ZEUS Study. <i>American Journal of Transplantation</i> , 2012, 12, 1528-1540.	4.7	77
82	Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 1999, 48, 694-703.	2.4	76
83	Three-Year Observational Follow-up of a Multicenter, Randomized Trial on Tacrolimus-Based Therapy with Withdrawal of Steroids or Mycophenolate Mofetil after Renal Transplant. <i>Transplantation</i> , 2006, 82, 55-61.	1.0	76
84	Effect of Food on Everolimus Absorption: Quantification in Healthy Subjects and a Confirmatory Screening in Patients with Renal Transplants. <i>Pharmacotherapy</i> , 2002, 22, 154-159.	2.6	75
85	Sotrastaurin, a Novel Small Molecule Inhibiting Protein-Kinase C: Randomized Phase II Study in Renal Transplant Recipients. <i>American Journal of Transplantation</i> , 2011, 11, 1444-1455.	4.7	75
86	Increased Incidence of Angioedema with ACE Inhibitors in Combination with mTOR Inhibitors in Kidney Transplant Recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 703-708.	4.5	74
87	MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 548-553.	2.4	72
88	Conversion From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Maintenance Renal Transplant Recipients Receiving Tacrolimus: Clinical, Pharmacokinetic, and Pharmacodynamic Outcomes. <i>Transplantation</i> , 2007, 83, 417-424.	1.0	71
89	Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T>C polymorphism. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 626-634.	1.5	71
90	Weight gain in long-term survivors of kidney or liver transplantationâ€”Another paradigm of sarcopenic obesity?. <i>Nutrition</i> , 2012, 28, 378-383.	2.4	71

#	ARTICLE	IF	CITATIONS
91	Immune response to an adjuvanted influenza A H1N1 vaccine (Pandemrix(R)) in renal transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 423-428.	0.7	69
92	Strategies to increase the donor pool and access to kidney transplantation: an international perspective. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 217-222.	0.7	68
93	Developing Consensus-Based Priority Outcome Domains for Trials in Kidney Transplantation. <i>Transplantation</i> , 2017, 101, 1875-1886.	1.0	68
94	Exploring the Complexity of Death-Censored Kidney Allograft Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1513-1526.	6.1	67
95	Interleukin-6 expression after renal transplantation. <i>Nephrology Dialysis Transplantation</i> , 1997, 12, 753-759.	0.7	66
96	Effect of Pregnancy on Long-Term Kidney Function in Renal Transplant Recipients Treated with Cyclosporine and with Azathioprine. <i>American Journal of Transplantation</i> , 2005, 5, 2732-2739.	4.7	66
97	TNF- α AND IL-1 β INDUCE APOPTOSIS IN SUBCONFLUENT RAT MESANGIAL CELLS. EVIDENCE FOR THE INVOLVEMENT OF HYDROGEN PEROXIDE AND LIPID PEROXIDATION AS SECOND MESSENGERS. <i>Cytokine</i> , 2000, 12, 986-991.	3.2	65
98	Therapeutic Drug Monitoring of Mycophenolic Acid in Solid Organ Transplant Patients Treated With Mycophenolate Mofetil: Review of the Literature. <i>Transplantation</i> , 2006, 82, 1004-1012.	1.0	65
99	Plasma Concentrations of Mycophenolic Acid Acyl Glucuronide Are Not Associated with Diarrhea in Renal Transplant Recipients. <i>American Journal of Transplantation</i> , 2007, 7, 1822-1831.	4.7	65
100	Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of The Transplantation Society consensus meeting. <i>Transplantation Reviews</i> , 2011, 25, 58-64.	2.9	65
101	The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation. <i>Transplantation Proceedings</i> , 1998, 30, 2195-2197.	0.6	64
102	<i>MDR1</i> Haplotypes Do Not Affect the Steady-State Pharmacokinetics of Cyclosporine in Renal Transplant Patients. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 1101-1107.	2.0	62
103	Does pre-emptive transplantation versus post start of dialysis transplantation with a kidney from a living donor improve outcomes after transplantation? A systematic literature review and position statement by the Descartes Working Group and ERBP. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 691-697.	0.7	62
104	Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients. <i>JCI Insight</i> , 2022, 7, .	5.0	62
105	Pharmacodynamic Monitoring of Mycophenolate Mofetil. <i>Clinical Chemistry and Laboratory Medicine</i> , 2000, 38, 1213-6.	2.3	60
106	Validation of Immunological Biomarkers for the Pharmacodynamic Monitoring of Immunosuppressive Drugs in Humans. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 77-86.	2.0	60
107	Epidemiological Approach to Identifying Genetic Predispositions for Atypical Hemolytic Uremic Syndrome. <i>Annals of Human Genetics</i> , 2010, 74, 17-26.	0.8	60
108	Use of Neoral C2 monitoring: a European consensus. <i>Transplant International</i> , 2005, 18, 768-778.	1.6	59

#	ARTICLE	IF	CITATIONS
109	Pharmacokinetic Principles of Immunosuppressive Drugs. American Journal of Transplantation, 2005, 5, 207-217.	4.7	59
110	Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat. American Journal of Physiology - Renal Physiology, 2008, 294, F440-F449.	2.7	58
111	Review of the Tuberous Sclerosis Renal Guidelines from the 2012 Consensus Conference: Current Data and Future Study. Nephron, 2016, 134, 51-58.	1.8	58
112	Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. British Journal of Clinical Pharmacology, 2010, 69, 346-357.	2.4	57
113	“Old-for-Old” Cadaveric Renal Transplantation: Surgical Findings, Perioperative Complications and Outcome. European Urology, 2003, 44, 701-708.	1.9	56
114	A Cardiovascular Risk Calculator for Renal Transplant Recipients. Transplantation, 2012, 94, 57-62.	1.0	56
115	The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation. Nephrology Dialysis Transplantation, 2004, 19, 2630-2633.	0.7	55
116	Biomarkers as a Tool for Management of Immunosuppression in Transplant Patients. Therapeutic Drug Monitoring, 2010, 32, 560-572.	2.0	54
117	The Severity of Acute Cellular Rejection Defined by Banff Classification Is Associated With Kidney Allograft Outcomes. Transplantation, 2014, 97, 1146-1154.	1.0	54
118	Clinical and Molecular Characterization of Patients with Heterozygous Mutations in Wilms Tumor Suppressor Gene 1. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 825-831.	4.5	52
119	Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis. Frontiers in Immunology, 2021, 12, 690698.	4.8	52
120	Serological Response to Three, Four and Five Doses of SARS-CoV-2 Vaccine in Kidney Transplant Recipients. Journal of Clinical Medicine, 2022, 11, 2565.	2.4	52
121	Improved diagnosis of early kidney allograft dysfunction by ultrasound with echo enhancer—a new method for the diagnosis of renal perfusion. Nephrology Dialysis Transplantation, 2006, 21, 2921-2929.	0.7	51
122	Improved Assay for the Nonradioactive Determination of Inosine 5'-Monophosphate Dehydrogenase Activity in Peripheral Blood Mononuclear Cells. Therapeutic Drug Monitoring, 2009, 31, 351-359.	2.0	51
123	Evaluation of the Effect of Tofacitinib Exposure on Outcomes in Kidney Transplant Patients. American Journal of Transplantation, 2015, 15, 1644-1653.	4.7	50
124	Urinary miR-155 and CXCL10 as prognostic and predictive biomarkers of rejection, graft outcome and treatment response in kidney transplantation. British Journal of Clinical Pharmacology, 2017, 83, 2636-2650.	2.4	49
125	Preformed Donor-Specific HLA Antibodies in Living and Deceased Donor Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1056-1066.	4.5	49
126	Renal Transplant Patients at High Risk of Acute Rejection Benefit From Adequate Exposure to Mycophenolic Acid. Transplantation, 2010, 89, 595-599.	1.0	48

#	ARTICLE	IF	CITATIONS
127	Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial. <i>Trials</i> , 2019, 20, 37.	1.6	48
128	Outcomes of Transplanting Deceased-Donor Kidneys between Elderly Donors and Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 37-40.	6.1	47
129	Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation. <i>American Journal of Transplantation</i> , 2018, 18, 1726-1734.	4.7	47
130	Experience with belatacept rescue therapy in kidney transplant recipients. <i>Transplant International</i> , 2016, 29, 1184-1195.	1.6	46
131	The DESCARTES-Nantes survey of kidney transplant recipients displaying clinical operational tolerance identifies 35 new tolerant patients and 34 almost tolerant patients. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1002-1013.	0.7	46
132	The Risk of Tumour Recurrence in Patients Undergoing Renal Transplantation for End-stage Renal Disease after Previous Treatment for a Urological Cancer: A Systematic Review. <i>European Urology</i> , 2018, 73, 94-108.	1.9	46
133	A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor. <i>American Journal of Transplantation</i> , 2018, 18, 2945-2954.	4.7	46
134	Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2003, 41, 470-476.	0.6	46
135	FTY720-induced lymphocyte homing modulates post-transplant preservation/reperfusion injury. <i>Kidney International</i> , 2004, 65, 1076-1083.	5.2	45
136	A Randomized Trial Comparing Renal Function in Older Kidney Transplant Patients Following Delayed Versus Immediate Tacrolimus Administration. <i>Transplantation</i> , 2009, 88, 1101-1108.	1.0	45
137	Review of Bortezomib Treatment of Antibody-Mediated Rejection in Renal Transplantation. <i>Antioxidants and Redox Signaling</i> , 2014, 21, 2401-2418.	5.4	45
138	Hyperlactatemia, Lactate Kinetics and Prediction of Citrate Accumulation in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy With Regional Citrate Anticoagulation. <i>Critical Care Medicine</i> , 2017, 45, e941-e946.	0.9	45
139	Cyclosporine A up-regulates the expression of TGF-beta1 and its receptors type I and type II in rat mesangial cells. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1568-1577.	0.7	44
140	â€Suspended in a paradoxâ€™-patient attitudes to wait-listing for kidney transplantation: systematic review and thematic synthesis of qualitative studies. <i>Transplant International</i> , 2015, 28, 771-787.	1.6	44
141	Graft Function, Cardiovascular Risk Factors, and Sex Hormones in Renal Transplant Recipients on an Immunosuppressive Regimen of Everolimus, Reduced Dose of Cyclosporine, and Basiliximab. <i>Transplantation Proceedings</i> , 2005, 37, 1601-1604.	0.6	43
142	Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 179-184.	1.5	43
143	Conversion to Belatacept in Maintenance Kidney Transplant Patients. <i>Transplantation</i> , 2018, 102, 1545-1552.	1.0	43
144	Impact of the variability of cyclosporin A trough levels on long-term renal allograft function. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1310-1317.	0.7	42

#	ARTICLE	IF	CITATIONS
145	Successful treatment of nephrogenic fibrosing dermopathy in a kidney transplant recipient with photodynamic therapy. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 220-222.	0.7	42
146	Treatment of PTLD with Rituximab and CHOP Reduces the Risk of Renal Graft Impairment after Reduction of Immunosuppression. <i>American Journal of Transplantation</i> , 2009, 9, 2331-2337.	4.7	42
147	The 'blood group O problem' in kidney transplantation--time to change?. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1998-2004.	0.7	42
148	Volume matters: CT-based renal cortex volume measurement in the evaluation of living kidney donors. <i>Transplant International</i> , 2013, 26, 1208-1216.	1.6	42
149	Recent advances in kidney transplantation: a viewpoint from the Descartes advisory board*. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1699-1707.	0.7	42
150	The value of C2 monitoring in stable renal allograft recipients on maintenance immunosuppression. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 215-222.	0.7	41
151	Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 2606-2614.	0.7	41
152	Improved Left Ventricular Structure and Function After Successful Kidney Transplantation. <i>Kidney and Blood Pressure Research</i> , 2016, 41, 701-709.	2.0	41
153	First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis. <i>PLoS ONE</i> , 2019, 14, e0212023.	2.5	41
154	Conversion from Calcineurin Inhibitor to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 3252-3264.	6.1	41
155	FTY720 exerts differential effects on CD4+ and CD8+ T-lymphocyte subpopulations expressing chemokine and adhesion receptors. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 702-713.	0.7	40
156	Pharmacokinetics of Intravenous, Single-Dose Tiotropium in Subjects with Different Degrees of Renal Impairment. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 163-172.	2.0	40
157	AcylMPAG Plasma Concentrations and Mycophenolic Acid-Related Side Effects in Patients Undergoing Renal Transplantation Are Not Related to the UGT2B7-840G>A Gene Polymorphism. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 439-444.	2.0	40
158	Pharmacokinetics and Pharmacodynamics of Intensified versus Standard Dosing of Mycophenolate Sodium in Renal Transplant Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 503-511.	4.5	40
159	Enteric-coated mycophenolate sodium. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 981-994.	2.4	40
160	Common Elements in Rare Kidney Diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2017, 92, 796-808.	5.2	40
161	The Preferences and Perspectives of Nephrologists on Patients' Access to Kidney Transplantation. <i>Transplantation</i> , 2014, 98, 682-691.	1.0	39
162	Efficacy of Sotrastaurin Plus Tacrolimus After De Novo Kidney Transplantation: Randomized, Phase II Trial Results. <i>American Journal of Transplantation</i> , 2013, 13, 1746-1756.	4.7	38

#	ARTICLE	IF	CITATIONS
163	Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-1 Mediated Podocyte α 3-integrin Activation. <i>Transplantation</i> , 2015, 99, 2593-2597.	1.0	38
164	Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor-induced nephrotoxicity. <i>Transplantation Proceedings</i> , 2001, 33, 3234-3235.	0.6	37
165	Hypertension in patients after renal transplantation. <i>Transplantation Proceedings</i> , 1997, 29, 209-211.	0.6	36
166	Assessment of the Kidney Donor Profile Index in a European cohort. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1465-1472.	0.7	36
167	The use of contrast-enhanced US in renal transplant: first results and potential clinical benefit. <i>European Radiology, Supplement</i> , 2005, 15, e109-e116.	1.4	35
168	Banff survey on antibody-mediated rejection clinical practices in kidney transplantation: Diagnostic misinterpretation has potential therapeutic implications. <i>American Journal of Transplantation</i> , 2019, 19, 123-131.	4.7	35
169	FTY720, a Novel Immunomodulator in de Novo Kidney Transplant Patients: Pharmacokinetics and Exposure-Response Relationship. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 1268-1278.	2.0	34
170	Enteric-Coated Mycophenolate Sodium Provides Higher Mycophenolic Acid Predose Levels Compared With Mycophenolate Mofetil: Implications for Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 381-384.	2.0	34
171	Sotrastaurin in Calcineurin Inhibitor-Free Regimen Using Everolimus in De Novo Kidney Transplant Recipients. <i>American Journal of Transplantation</i> , 2013, 13, 1757-1768.	4.7	34
172	Anti-thymocyte globulins in kidney transplantation: focus on current indications and long-term immunological side effects. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw368.	0.7	34
173	Transmission of breast cancer by a single multiorgan donor to 4 transplant recipients. <i>American Journal of Transplantation</i> , 2018, 18, 1810-1814.	4.7	34
174	Treatment of membranous glomerulopathy with cyclosporin A: how much patience is required?. <i>Nephrology Dialysis Transplantation</i> , 1999, 14, 1036-1038.	0.7	33
175	PRACTICE VARIATIONS IN THE EVALUATION OF ADULT CANDIDATES FOR CADAVERIC KIDNEY TRANSPLANTATION. <i>Transplantation</i> , 2000, 70, 1492-1497.	1.0	33
176	Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study. <i>Clinical Nephrology</i> , 2015, 83 (2015), 11-21.	0.7	33
177	Need for optimized immunosuppression in elderly kidney transplant recipients. <i>Transplantation Reviews</i> , 2015, 29, 237-239.	2.9	33
178	Prophylaxis and treatment of <i>Pneumocystis Jirovecii</i> pneumonia after solid organ transplantation. <i>Pharmacological Research</i> , 2018, 134, 61-67.	7.1	33
179	Pregnancy on Intensified Hemodialysis: Fetal Surveillance and Perinatal Outcome. <i>Fetal Diagnosis and Therapy</i> , 2007, 22, 289-293.	1.4	32
180	Effects of sotrastaurin, mycophenolic acid and everolimus on human B-lymphocyte function and activation. <i>Transplant International</i> , 2012, 25, 1106-1116.	1.6	32

#	ARTICLE	IF	CITATIONS
181	Identification of T Cell-Mediated Vascular Rejection After Kidney Transplantation by the Combined Measurement of 5 Specific MicroRNAs in Blood. <i>Transplantation</i> , 2016, 100, 898-907.	1.0	32
182	Clinical Outcome of Patients With De Novo C1q-Binding Donor-Specific HLA Antibodies After Renal Transplantation. <i>Transplantation</i> , 2017, 101, 2165-2174.	1.0	32
183	Glomerular activin A overexpression is linked to fibrosis in anti-Thy1 glomerulonephritis. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 319-328.	0.7	31
184	Laparoscopic versus Open Donor Nephrectomy in Germany: Impact on Donor Health-Related Quality of Life and Willingness to Donate. <i>Transplantation Proceedings</i> , 2005, 37, 2011-2015.	0.6	31
185	Biomarkers of Over-Immunosuppression. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 316-322.	4.7	31
186	Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1060-1070.	0.7	31
187	Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1000-1008.	0.7	31
188	Reports of Large Immunosuppression Trials in Kidney Transplantation: Room for Improvement. <i>American Journal of Transplantation</i> , 2004, 4, 738-743.	4.7	30
189	Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 361-372.	2.4	30
190	Pretransplant virtual PRA and long-term outcomes of kidney transplant recipients. <i>Transplant International</i> , 2015, 28, 710-719.	1.6	30
191	Standardized Outcomes in Nephrology-Transplantation: A Global Initiative to Develop a Core Outcome Set for Trials in Kidney Transplantation. <i>Transplantation Direct</i> , 2016, 2, e79.	1.6	30
192	Factors associated with kidney graft survival in pure antibody-mediated rejection at the time of indication biopsy: Importance of parenchymal injury but not disease activity. <i>American Journal of Transplantation</i> , 2021, 21, 1391-1401.	4.7	30
193	Interleukin-8 expression in patients after renal transplantation. <i>American Journal of Kidney Diseases</i> , 1997, 29, 871-880.	1.9	29
194	Age-Related Penetrance of Hereditary Atypical Hemolytic Uremic Syndrome. <i>Annals of Human Genetics</i> , 2011, 75, 639-647.	0.8	29
195	Transplanting HCV-Infected Kidneys into Uninfected Recipients. <i>New England Journal of Medicine</i> , 2017, 377, 1103-1105.	27.0	29
196	Treatment of acute c-ANCA-positive vasculitis with mycophenolate mofetil. <i>American Journal of Kidney Diseases</i> , 1999, 34, e9.1-e9.6.	1.9	28
197	Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 103-113.	3.3	28
198	European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 563-573.	0.7	28

#	ARTICLE	IF	CITATIONS
199	Pregnancy following kidney transplantation - impact on mother and graft function and focus on childrensâ€™ longitudinal development. BMC Pregnancy and Childbirth, 2019, 19, 376.	2.4	28
200	The underestimated burden of monogenic kidney disease in adults waitlisted for kidney transplantation. Genetics in Medicine, 2021, 23, 1219-1224.	2.4	28
201	Conversion to sirolimus for chronic allograft dysfunction: long-term results confirm predictive value of proteinuria. Transplant International, 2007, 21, 071115125226003-???.	1.6	27
202	Arrival Time Parametric Imaging: A New Ultrasound Technique for Quantifying Perfusion of Kidney Grafts. Ultraschall in Der Medizin, 2008, 29, 418-423.	1.5	27
203	Limited Sampling Strategies Drawn Within 3 Hours Postdose Poorly Predict Mycophenolic Acid Area-Under-the-Curve After Enteric-Coated Mycophenolate Sodium. Therapeutic Drug Monitoring, 2009, 31, 585-591.	2.0	27
204	Identification and Therapeutic Management of Highly Sensitized Patients Undergoing Renal Transplantation. Drugs, 2012, 72, 1335-1354.	10.9	27
205	Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients. Pediatric Nephrology, 2017, 32, 1137-1144.	1.7	27
206	Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangiomyomatosis. PLoS ONE, 2018, 13, e0201005.	2.5	27
207	Gadolinium-enhanced three-dimensional magnetic resonance angiography versus conventional digital subtraction angiography: which modality is superior in evaluating living kidney donors?1. Transplantation, 2003, 76, 1000-1002.	1.0	26
208	Safety and Efficacy of Intensified Versus Standard Dosing Regimens of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Patients. Transplantation, 2011, 91, 779-785.	1.0	26
209	An evaluation of sirolimus in renal transplantation. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 1337-1356.	3.3	26
210	Dynamics and epitope specificity of anti-human leukocyte antibodies following renal allograft nephrectomy. Nephrology Dialysis Transplantation, 2016, 31, 1351-1359.	0.7	26
211	Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4â€‘year results from the randomized <sc>EXIST</sc>â€‘1 and <sc>EXIST</sc>â€‘2 studies. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1796-1803.	2.4	26
212	Range and Consistency of Outcomes Reported in Randomized Trials Conducted in Kidney Transplant Recipients: A Systematic Review. Transplantation, 2018, 102, 2065-2071.	1.0	26
213	Inosine 5â€‘-monophosphate dehydrogenase activity as a biomarker in the field of transplantation. Clinica Chimica Acta, 2012, 413, 1391-1397.	1.1	25
214	Immunosuppression in the elderly renal allograft recipient: a systematic review. Transplantation Reviews, 2016, 30, 144-153.	2.9	25
215	â€‘1 feel stronger and younger all the timeâ€™ perspectives of elderly kidney transplant recipients: thematic synthesis of qualitative research. Nephrology Dialysis Transplantation, 2016, 31, 1531-1540.	0.7	25
216	<sc>LCPT</sc>onceâ€‘daily extendedâ€‘release tacrolimus tablets versus twiceâ€‘daily capsules: a pooled analysis of two phase 3 trials in important <i>de novo</i> and stable kidney transplant recipient subgroups. Transplant International, 2016, 29, 603-611.	1.6	25

#	ARTICLE	IF	CITATIONS
217	TBC1D8B Mutations Implicate RAB11-Dependent Vesicular Trafficking in the Pathogenesis of Nephrotic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2338-2353.	6.1	25
218	Pharmacodynamic monitoring of mycophenolate mofetil in stable renal allograft recipients. <i>Transplantation Proceedings</i> , 2002, 34, 1748-1750.	0.6	24
219	Sirolimus and lymphocele formation after kidney transplantation: an immunosuppressive medication as co-factor for a surgical problem?. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 448-449.	0.7	24
220	Pharmacodynamic Evaluation of the First Dose of Mycophenolate Mofetil Before Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 936-942.	4.5	24
221	eHealth in transplantation. <i>Transplant International</i> , 2021, 34, 16-26.	1.6	24
222	TBase - an Integrated Electronic Health Record and Research Database for Kidney Transplant Recipients. <i>Journal of Visualized Experiments</i> , 2021, , .	0.3	24
223	Limitations of C2 monitoring in renal transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 1463-1470.	0.7	23
224	S1P modulator FTY720 limits matrix expansion in acute anti-thy1 mesangioproliferative glomerulonephritis. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 292, F1761-F1770.	2.7	23
225	Pre-operative assessment of living renal transplant donors with state-of-the-art imaging modalities: computed tomography angiography versus magnetic resonance angiography in 118 patients. <i>World Journal of Urology</i> , 2013, 31, 983-990.	2.2	23
226	Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangiomyomatosis. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 958-970.	2.4	23
227	Risk Evaluation and Outcome of <i>Pneumocystis jirovecii</i> Pneumonia in Kidney Transplant Patients. <i>Transplantation Proceedings</i> , 2016, 48, 2924-2930.	0.6	23
228	Validation of the Living Kidney Donor Profile Index in a European cohort and comparison of long-term outcomes with US results. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1063-1070.	0.7	23
229	Treatment of secondary pulmonary hypertension with bosentan and its pharmacokinetic monitoring in ESRD. <i>American Journal of Kidney Diseases</i> , 2004, 43, 923-926.	1.9	22
230	Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid After Enteric-Coated Mycophenolate Versus Mycophenolate Mofetil in Patients With Progressive IgA Nephritis. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 850-859.	2.0	22
231	The inferior impact of antibody-mediated rejection on the clinical outcome of kidney allografts that develop <i>de novo</i> thrombotic microangiopathy. <i>Clinical Transplantation</i> , 2016, 30, 105-117.	1.6	22
232	Any Progress in the Treatment of Antibody-Mediated Rejection?. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 350-352.	6.1	22
233	Clinical Characteristics of Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex. <i>Frontiers in Neurology</i> , 2019, 10, 705.	2.4	22
234	Critical Illness and Systemic Inflammation Are Key Risk Factors of Severe Acute Kidney Injury in Patients With COVID-19. <i>Kidney International Reports</i> , 2021, 6, 905-915.	0.8	22

#	ARTICLE	IF	CITATIONS
235	Accuracy of a Novel SARS-CoV-2 Antigen-Detecting Rapid Diagnostic Test from Standardized Self-Collected Anterior Nasal Swabs. <i>Journal of Clinical Medicine</i> , 2021, 10, 2099.	2.4	22
236	Safety and Efficacy After Conversion From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium: Results of a 1-Year Extension Study. <i>Transplantation Proceedings</i> , 2005, 37, 912-915.	0.6	21
237	Immunologic outcome in elderly kidney transplant recipients: is it time for HLA-DR matching?. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 2143-2149.	0.7	21
238	Early Postoperative Basal Insulin Therapy versus Standard of Care for the Prevention of Diabetes Mellitus after Kidney Transplantation: A Multicenter Randomized Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2083-2098.	6.1	21
239	Patients with steroid refractory acute vascular rejection develop agonistic antibodies targeting angiotensin II type 1 receptor. <i>Transplantation Proceedings</i> , 2003, 35, 2104-2105.	0.6	20
240	Efficacy and Safety of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Recipients: Pooled Data From Three 12-Month Multicenter, Open-Label, Prospective Studies. <i>Transplantation Proceedings</i> , 2007, 39, 1386-1391.	0.6	20
241	MicroRNA regulation in blood cells of renal transplanted patients with interstitial fibrosis/tubular atrophy and antibody-mediated rejection. <i>PLoS ONE</i> , 2018, 13, e0201925.	2.5	20
242	Diagnostic Utility of Exome Sequencing for Kidney Disease. <i>New England Journal of Medicine</i> , 2019, 380, 2078-2081.	27.0	20
243	Substitution of conventional cyclosporin with a new microemulsion formulation in renal transplant patients: results after 1 year. <i>Nephrology Dialysis Transplantation</i> , 1996, 11, 165-172.	0.7	19
244	Recognition of Critical Situations from Time Series of Laboratory Results by Case-Based Reasoning. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2002, 9, 520-528.	4.4	19
245	FTY720: early clinical experience. <i>Transplantation Proceedings</i> , 2004, 36, S544-S548.	0.6	19
246	Current perspectives on FTY720. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 505-518.	4.1	19
247	Immunosuppression in renal transplantation: some aspects for the modern era. <i>Transplantation Reviews</i> , 2008, 22, 241-251.	2.9	19
248	Clinical Utility of a New Enzymatic Assay for Determination of Mycophenolic Acid in Comparison With an Optimized LC-MS/MS Method. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 218-223.	2.0	19
249	Comparison of first and second kidney transplants from the same deceased donor. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 4055-4061.	0.7	19
250	Genetic polymorphisms in <i>IL2</i> , <i>IL10</i> , <i>TGFβ1</i> , and <i>IL2</i> <i>RB</i> and acute rejection in renal transplant patients. <i>Clinical Transplantation</i> , 2014, 28, 649-655.	1.6	19
251	Adjustment of target weight based on absolute blood volume reduces the frequency of intradialytic morbid events. <i>Hemodialysis International</i> , 2018, 22, 254-260.	0.9	19
252	Efficacy and Safety of a Tofacitinib-based Immunosuppressive Regimen After Kidney Transplantation: Results From a Long-term Extension Trial. <i>Transplantation Direct</i> , 2018, 4, e380.	1.6	19

#	ARTICLE	IF	CITATIONS
253	Cyclosporine absorption profiling and therapeutic drug monitoring using c2 blood levels in stable renal allograft recipients. <i>Transplantation Proceedings</i> , 2002, 34, 1738-1739.	0.6	18
254	Effects of the new immunosuppressive agent AEB071 on human immune cells. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2159-2167.	0.7	18
255	Inosine monophosphate dehydrogenase activity in paediatrics: age-related regulation and response to mycophenolic acid. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 913-922.	1.9	18
256	Clindamycinâ€“primaquine for pneumocystis jiroveci pneumonia in renal transplant patients. <i>Infection</i> , 2014, 42, 981-989.	4.7	18
257	Evaluation of adherence and tolerability of prolongedâ€“release tacrolimus (Advagrafâ„¢) in kidney transplant patients in Germany: A multicenter, noninterventional study. <i>Clinical Transplantation</i> , 2018, 32, e13142.	1.6	18
258	Newly Diagnosed and Growing Subependymal Giant Cell Astrocytoma in Adults With Tuberous Sclerosis Complex: Results From the International TOSCA Study. <i>Frontiers in Neurology</i> , 2019, 10, 821.	2.4	18
259	Clinical Outcome Prediction from Admission Notes using Self-Supervised Knowledge Integration. , 2021, , .		18
260	Surrogate Endpoints for Late Kidney Transplantation Failure. <i>Transplant International</i> , 0, 35, .	1.6	18
261	The influence of age on outcome after renal transplantation. <i>Geriatric Nephrology and Urology</i> , 1997, 7, 137-146.	0.3	17
262	Conversion to Enteric-Coated Mycophenolate Sodium From Various Doses of Mycophenolate Mofetil: Results of a Prospective International Multicenter Trial in Maintenance Renal Transplant Patients Receiving Cyclosporine. <i>Transplantation Proceedings</i> , 2006, 38, 2856-2859.	0.6	17
263	Tabebuia avellanedae extracts inhibit IL-2-independent T-lymphocyte activation and proliferation. <i>Transplant Immunology</i> , 2008, 18, 319-323.	1.2	17
264	Pharmacokinetics of Sotrostauroin Combined With Tacrolimus or Mycophenolic Acid in De Novo Kidney Transplant Recipients. <i>Transplantation</i> , 2011, 91, 317-322.	1.0	17
265	Enteric-coated mycophenolate sodium immunosuppression in renal transplant patients: efficacy and dosing. <i>Transplantation Reviews</i> , 2012, 26, 233-240.	2.9	17
266	Acute cellular rejection with isolated v-lesions is not associated with more favorable outcomes than vascular rejection with more tubulointerstitial inflammations. <i>Clinical Transplantation</i> , 2014, 28, 410-418.	1.6	17
267	Free microRNA levels in plasma distinguish T-cell mediated rejection from stable graft function after kidney transplantation. <i>Transplant Immunology</i> , 2016, 39, 52-59.	1.2	17
268	Optimization of tacrolimus in kidney transplantation: New pharmacokinetic perspectives. <i>Transplantation Reviews</i> , 2020, 34, 100531.	2.9	17
269	Undoubtedly, kidney transplant recipients have a higher mortality due to COVIDâ€“19 disease compared to the general population. <i>Transplant International</i> , 2021, 34, 769-771.	1.6	17
270	How Delayed Graft Function Impacts Exposure to Mycophenolic Acid in Patients After Renal Transplantation. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 155-164.	2.0	17

#	ARTICLE	IF	CITATIONS
271	Differing proteinuria control with cyclosporin and tacrolimus. <i>Lancet, The</i> , 1997, 349, 330.	13.7	16
272	20-year experience with elderly donors in living renal transplantation. <i>Transplantation Proceedings</i> , 2003, 35, 2855-2857.	0.6	16
273	The impact of FTY720 (fingolimod) on vasodilatory function and arterial elasticity in renal transplant patients. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 2354-2358.	0.7	16
274	The lymphocyte migration inhibitor FTY720 attenuates experimental hypertensive nephropathy. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 297, F218-F227.	2.7	16
275	No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1086-1096.	2.4	16
276	Renal function to 5 years after late conversion of kidney transplant patients to everolimus: a randomized trial. <i>Journal of Nephrology</i> , 2015, 28, 115-123.	2.0	16
277	Rituximab in Combination With Bortezomib, Plasmapheresis, and High-Dose IVIG to Treat Antibody-Mediated Renal Allograft Rejection. <i>Transplantation Direct</i> , 2016, 2, e91.	1.6	16
278	Analysis of the Effects of Day-Time vs. Night-Time Surgery on Renal Transplant Patient Outcomes. <i>Journal of Clinical Medicine</i> , 2019, 8, 1051.	2.4	16
279	Natural clusters of tuberous sclerosis complex (TSC)-associated neuropsychiatric disorders (TAND): new findings from the TOSCA TAND research project. <i>Journal of Neurodevelopmental Disorders</i> , 2020, 12, 24.	3.1	16
280	SUCCESSFUL LIVING RELATED KIDNEY TRANSPLANTATION DESPITE RENAL ANGIOMYOLIPOMA IN SITU. <i>Journal of Urology</i> , 1999, 162, 480-481.	0.4	15
281	Reactivation of tuberculosis after conversion from azathioprine to mycophenolate mofetil 16 years after renal transplantation. <i>American Journal of Kidney Diseases</i> , 2000, 35, e12.1-e12.5.	1.9	15
282	Increased frequency of lymphoceles under treatment with sirolimus following renal transplantation: a single center experience. <i>Transplantation Proceedings</i> , 2002, 34, 1815-1816.	0.6	15
283	Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients. <i>Transplantation Proceedings</i> , 2004, 36, S524-S527.	0.6	15
284	Lectin-like oxidized low-density lipoprotein (LDL) receptor (LOX-1)-mediated pathway and vascular oxidative injury in older-age rat renal transplants. <i>Kidney International</i> , 2005, 67, 1583-1594.	5.2	15
285	Efficacy and safety of enteric-coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials. <i>Clinical Transplantation</i> , 2007, 21, 117-125.	1.6	15
286	Reduction of Gastrointestinal Complications in Renal Graft Recipients after Conversion from Mycophenolate Mofetil to Enteric-coated Mycophenolate Sodium. <i>Transplantation Proceedings</i> , 2011, 43, 1641-1646.	0.6	15
287	Unacceptable human leucocyte antigens for organ offers in the era of organ shortage: influence on waiting time before kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 880-889.	0.7	15
288	Late Conversion to Belatacept After Kidney Transplantation: Outcome and Prognostic Factors. <i>Transplantation Proceedings</i> , 2017, 49, 1747-1756.e1.	0.6	15

#	ARTICLE	IF	CITATIONS
289	Pre-existing malignancies in renal transplant candidatesâ€”time to reconsider waiting times. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1292-1300.	0.7	15
290	Robot-Assisted versus Laparoscopic Donor Nephrectomy: A Comparison of 250 Cases. <i>Journal of Clinical Medicine</i> , 2020, 9, 1610.	2.4	15
291	A 2020 Banff Antibodyâ€”mediated Injury Working Group examination of international practices for diagnosing antibodyâ€”mediated rejection in kidney transplantation â€” a cohort study. <i>Transplant International</i> , 2021, 34, 488-498.	1.6	15
292	Rare manifestations and malignancies in tuberous sclerosis complex: findings from the Tuberous Sclerosis registry to increase disease awareness (TOSCA). <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 301.	2.7	15
293	Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab. <i>Clinical Nephrology</i> , 2007, 67, 164-175.	0.7	15
294	Absolute or Relative Quantification of Donor-derived Cell-free DNA in Kidney Transplant Recipients: Case Series. <i>Transplantation Direct</i> , 2021, 7, e778.	1.6	15
295	Conversion to Mycophenolate Mofetil for Chronic Progressive Deterioration of Renal Allograft Function: First Clinical Experiences in 44 Patients. <i>Transplantation Proceedings</i> , 1998, 30, 1190-1191.	0.6	14
296	Reporting of Rejection after Renal Transplantation in Large Immunosuppressive Trials: Biopsy-Proven, Clinical, Presumed, or Treated Rejection?. <i>Transplantation</i> , 2006, 81, 655-659.	1.0	14
297	Nonâ€”invasive imaging of living kidney donors: intraindividual comparison of multislice computed tomography angiography with magnetic resonance angiography. <i>Clinical Transplantation</i> , 2012, 26, E412-7.	1.6	14
298	The Clinical Data Intelligence Project. <i>Informatik-Spektrum</i> , 2016, 39, 290-300.	1.3	14
299	Treatment of Acute Antibody-Mediated Renal Allograft Rejection With Cyclophosphamide. <i>Transplantation</i> , 2017, 101, 2545-2552.	1.0	14
300	Extended-Spectrum Beta-Lactamaseâ€”Producing Enterobacteriaceae â€”Related Urinary Tract Infection in Kidney Transplant Recipients: Risk Factors, Treatment, and Long-Term Outcome. <i>Transplantation Proceedings</i> , 2017, 49, 1757-1765.	0.6	14
301	Impact of Pre-existing Comorbidities on Long-term Outcomes in Kidney Transplant Recipients. <i>Transplantation Proceedings</i> , 2018, 50, 3232-3241.	0.6	14
302	Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials. <i>BMC Nephrology</i> , 2018, 19, 237.	1.8	14
303	The regulation of interferon type I pathwayâ€”related genes RSAD2 and ETV7 specifically indicates antibodyâ€”mediated rejection after kidney transplantation. <i>Clinical Transplantation</i> , 2018, 32, e13429.	1.6	14
304	Effectiveness and Harms of Using Kidneys with Small Renal Tumors from Deceased or Living Donors as a Source of Renal Transplantation: A Systematic Review. <i>European Urology Focus</i> , 2019, 5, 508-517.	3.1	14
305	Autoantibodies from Patients with Scleroderma Renal Crisis Promote PAR-1 Receptor Activation and IL-6 Production in Endothelial Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11793.	4.1	14
306	Antibody therapy in steroid-resistant rejection. <i>Transplantation Proceedings</i> , 1998, 30, 1778-1779.	0.6	13

#	ARTICLE	IF	CITATIONS
307	Impact of cyclosporine on the development of immunosuppressive therapy. Transplantation Proceedings, 2004, 36, S130-S134.	0.6	13
308	FTY720 MEDIATES APOPTOSIS-INDEPENDENT LYMPHOPENIA IN HUMAN RENAL ALLOGRAFT RECIPIENTS: DIFFERENT EFFECTS ON CD62L+ AND CCR5+ T LYMPHOCYTES. Transplantation, 2004, 77, 1424-1432.	1.0	13
309	Attitude to nephrolithiasis in the potential living kidney donor: a survey of the German kidney transplant centers and review of the literature. Clinical Transplantation, 2008, 22, 476-483.	1.6	13
310	Proteinuria and sirolimus after renal transplantation: a retrospective analysis from a large <scp>German multicenter database. Clinical Transplantation, 2014, 28, 67-79.	1.6	13
311	Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients. Transplantation, 2017, 101, 2780-2788.	1.0	13
312	High frequency of valganciclovir underdosing for cytomegalovirus prophylaxis after renal transplantation. CKJ: Clinical Kidney Journal, 2018, 11, 564-573.	2.9	13
313	Sclerotic bone lesions as a potential imaging biomarker for the diagnosis of tuberous sclerosis complex. Scientific Reports, 2018, 8, 953.	3.3	13
314	Low Seroprevalence of SARS-CoV-2 Antibodies during Systematic Antibody Screening and Serum Responses in Patients after COVID-19 in a German Transplant Center. Journal of Clinical Medicine, 2020, 9, 3401.	2.4	13
315	Patient-Reported Outcomes as Endpoints in Clinical Trials of Kidney Transplantation Interventions. Transplant International, 0, 35, .	1.6	13
316	Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials. Expert Opinion on Emerging Drugs, 2022, 27, 151-167.	2.4	13
317	Prospective randomized pilot study of steroid withdrawal with mycophenolate mofetil in long-term cyclosporine-treated patients: 4-year follow-up. Transplantation Proceedings, 2002, 34, 1703-1706.	0.6	12
318	Influence of Everolimus on Steady-State Pharmacokinetics of Cyclosporine in Maintenance Renal Transplant Patients. Journal of Clinical Pharmacology, 2005, 45, 781-791.	2.0	12
319	Steroid- and calcineurin inhibitor free immunosuppression in kidney transplantation: state of the art and future developments. World Journal of Urology, 2007, 25, 325-332.	2.2	12
320	Combined standard and novel immunosuppressive substances affect B-lymphocyte function. International Immunopharmacology, 2013, 15, 718-725.	3.8	12
321	Belatacept utilization recommendations: an expert position. Expert Opinion on Drug Safety, 2013, 12, 111-122.	2.4	12
322	Complement-Binding Anti-HLA Antibodies and Kidney Transplantation. New England Journal of Medicine, 2014, 370, 83-86.	27.0	12
323	The Relationship of the Severity and Category of Acute Rejection With Intimal Arteritis Defined in Banff Classification to Clinical Outcomes. Transplantation, 2015, 99, e105-e114.	1.0	12
324	Bioavailability and costs of onceâ€daily and twiceâ€daily tacrolimus formulations in de novo kidney transplantation. Clinical Transplantation, 2018, 32, e13311.	1.6	12

#	ARTICLE	IF	CITATIONS
325	Standard work-up of the low-risk kidney transplant candidate: a European expert survey of the ERA-EDTA Developing Education Science and Care for Renal Transplantation in European States Working Group. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1605-1611.	0.7	12
326	Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept. <i>BMC Nephrology</i> , 2020, 21, 354.	1.8	12
327	Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC). <i>PLoS ONE</i> , 2017, 12, e0189132.	2.5	12
328	The diagnostic value of GM-CSF and IL-6 determinations in patients after renal transplantation. <i>Transplant International</i> , 1994, 7, 97-101.	1.6	11
329	Glomerular epithelial cell products stimulate mesangial cell proliferation in culture. <i>Kidney International</i> , 1997, 52, 733-741.	5.2	11
330	Novel Mediators of FTY720 in Human Lymphocytes. <i>Transplantation</i> , 2005, 79, 492-495.	1.0	11
331	Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients. <i>Cytokine</i> , 2008, 42, 306-311.	3.2	11
332	Improved Rejection Prophylaxis With an Initially Intensified Dosing Regimen of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Recipients. <i>Transplantation</i> , 2011, 92, 321-327.	1.0	11
333	Building a network of ADPKD reference centres across Europe: the EuroCYST initiative. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, iv26-iv32.	0.7	11
334	Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy. <i>American Journal of Transplantation</i> , 2018, 18, 2965-2976.	4.7	11
335	Native Nephrectomy before and after Renal Transplantation in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). <i>Journal of Clinical Medicine</i> , 2019, 8, 1622.	2.4	11
336	Treatment Patterns and Use of Resources in Patients With Tuberous Sclerosis Complex: Insights From the TOSCA Registry. <i>Frontiers in Neurology</i> , 2019, 10, 1144.	2.4	11
337	A randomized controlled trial-based algorithm for insulin-pump therapy in hyperglycemic patients early after kidney transplantation. <i>PLoS ONE</i> , 2018, 13, e0193569.	2.5	11
338	Mycophenolate mofetil pharmacokinetics in renal transplant recipients on peritoneal dialysis. <i>Transplant International</i> , 1998, 11, 53-57.	1.6	10
339	Pharmacokinetics and pharmacodynamics of mycophenolate mofetil under oral and intravenous therapy. <i>Transplantation Proceedings</i> , 2002, 34, 1745-1747.	0.6	10
340	Relevance and meaning of prostate cancer in kidney transplantation. <i>Transplantation Proceedings</i> , 2002, 34, 2225-2226.	0.6	10
341	Effect of Mycophenolate Mofetil Monotherapy on T-Cell Functions and Inosine Monophosphate Dehydrogenase Activity in Patients Undergoing a Kidney Transplantation. <i>Transplantation Proceedings</i> , 2006, 38, 2292-2294.	0.6	10
342	Superior Efficacy of Enteric-coated Mycophenolate vs Mycophenolate Mofetil in De Novo Transplant Recipients: Pooled Analysis. <i>Transplantation Proceedings</i> , 2010, 42, 1325-1328.	0.6	10

#	ARTICLE	IF	CITATIONS
343	Sirolimus for secondary SCC prevention in renal transplantation. <i>Nature Reviews Nephrology</i> , 2012, 8, 687-689.	9.6	10
344	New Perspectives of Immunosuppression. <i>Transplantation Proceedings</i> , 2013, 45, 1224-1231.	0.6	10
345	The efficacy and safety of cyclosporine reduction in <i>de novo</i> renal allograft patients receiving sirolimus and corticosteroids: results from an open-label comparative study. <i>Transplant International</i> , 2014, 27, 176-186.	1.6	10
346	Clinical outcome of norovirus infection in renal transplant patients. <i>Clinical Transplantation</i> , 2016, 30, 1283-1293.	1.6	10
347	Incidence of Infectious Disease and Malignancies After Rituximab Therapy in Kidney Transplant Recipients: Results From a Cohort in Germany. <i>Transplantation Proceedings</i> , 2017, 49, 2269-2273.	0.6	10
348	Treatment of Antibody-Mediated Renal Allograft Rejection: Improving Step by Step. <i>Journal of Immunology Research</i> , 2017, 2017, 1-9.	2.2	10
349	Tuberous Sclerosis registry to increase disease awareness (TOSCA) Post-Authorisation Safety Study of Everolimus in Patients With Tuberous Sclerosis Complex. <i>Frontiers in Neurology</i> , 2021, 12, 630378.	2.4	10
350	HUMAN SAFETY AND PHARMACOLOGY OF FTY 720. <i>Transplantation</i> , 1999, 67, S153.	1.0	10
351	Proposed Definitions of T Cell-Mediated Rejection and Tubulointerstitial Inflammation as Clinical Trial Endpoints in Kidney Transplantation. <i>Transplant International</i> , 0, 35, .	1.6	10
352	Alloimmune Risk Stratification for Kidney Transplant Rejection. <i>Transplant International</i> , 0, 35, .	1.6	10
353	Effectiveness of deferred therapy with ganciclovir in renal allograft recipients with cytomegalovirus disease. <i>Transplantation Proceedings</i> , 1998, 30, 2083-2085.	0.6	9
354	RE: SUCCESSFUL LIVING RELATED KIDNEY TRANSPLANTATION DESPITE RENAL ANGIOMYOLIPOMA IN SITU. <i>Journal of Urology</i> , 2000, 163, 924-924.	0.4	9
355	Laparoscopic donor nephrectomy in Germany. <i>Transplantation Proceedings</i> , 2002, 34, 3099-3101.	0.6	9
356	Mycophenolate mofetil maintenance therapy in renal transplant patients: long-term results of the <i>ranC</i> <i>STAY</i> study. <i>Clinical Transplantation</i> , 2012, 26, 919-926.	1.6	9
357	Frequency and long-term outcomes of post-transplant hypophosphatemia after kidney transplantation. <i>Transplant International</i> , 2013, 26, e94-e96.	1.6	9
358	Secreted frizzled-related protein 4 predicts progression of autosomal dominant polycystic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2015, 31, gfv077.	0.7	9
359	Advances in pharmacotherapy to treat kidney transplant rejection. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1627-1648.	1.8	9
360	Immunosuppression and Results in Renal Transplantation. <i>European Urology Supplements</i> , 2016, 15, 415-429.	0.1	9

#	ARTICLE	IF	CITATIONS
361	Long-Term Outcomes of Kidney Transplant Recipients With Primary Idiopathic Focal Segmental Glomerulosclerosis. <i>Transplantation Proceedings</i> , 2017, 49, 2256-2259.	0.6	9
362	A novel tool for the identification of correlations in medical data by faceted search. <i>Computers in Biology and Medicine</i> , 2017, 85, 98-105.	7.0	9
363	Investigation of the physical and psychosocial outcomes after living kidney donation - a multicenter cohort study (SoLKID - Safety of Living Kidney Donors). <i>BMC Nephrology</i> , 2018, 19, 83.	1.8	9
364	Discovering novel injury features in kidney transplant biopsies associated with TCMR and donor aging. <i>American Journal of Transplantation</i> , 2021, 21, 1725-1739.	4.7	9
365	Early prognostic performance of miR155-5p monitoring for the risk of rejection: Logistic regression with a population pharmacokinetic approach in adult kidney transplant patients. <i>PLoS ONE</i> , 2021, 16, e0245880.	2.5	9
366	Assertion Detection in Clinical Notes: Medical Language Models to the Rescue?. , 2021, , .		9
367	Sirolimus in renal transplant recipients with malignancies in Germany. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 2047-2058.	2.9	9
368	HUMAN PHARMACOKINETICS OF FTY 720. <i>Transplantation</i> , 1999, 67, S204.	1.0	9
369	De-novo malignancies after kidney transplantation: A long-term observational study. <i>PLoS ONE</i> , 2020, 15, e0242805.	2.5	9
370	Early conversion from cyclosporine to everolimus following living-donor kidney transplantation: outcomes at 5 years posttransplant in the randomized ZEUS trial. <i>Clinical Nephrology</i> , 2016, 85 (2016), 215-225.	0.7	9
371	Pharmacodynamics of FTY720, the first member of a new class of immune-modulating therapeutics in transplantation medicine. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2003, 41, 482-487.	0.6	9
372	Determination of unacceptable <scp>HLA</scp> antigen mismatches in kidney transplant recipients. <i>Hla</i> , 2022, 100, 3-17.	0.6	9
373	Predictors of Serological Response to SARS-CoV-2 Vaccination in Kidney Transplant Patients: Baseline Characteristics, Immunosuppression, and the Role of IMPDH Monitoring. <i>Journal of Clinical Medicine</i> , 2022, 11, 1697.	2.4	9
374	Prolonged-Release Once-Daily Formulation of Tacrolimus Versus Standard-of-Care Tacrolimus in de novo Kidney Transplant Patients Across Europe. <i>Transplant International</i> , 0, 35, .	1.6	9
375	Allograft Function as Endpoint for Clinical Trials in Kidney Transplantation. <i>Transplant International</i> , 0, 35, .	1.6	9
376	Optimizing neoral therapeutic drug monitoring with cyclosporine trough (C0) and C2 concentrations in stable renal allograft recipients. <i>Transplantation Proceedings</i> , 2001, 33, 3102-3103.	0.6	8
377	Pharmacodynamic monitoring of lymphocyte proliferation and TGF- β 1 expression at cyclosporine a (CyA) trough levels (C0) and 2 hours after intake (C2) of CyA in human renal allograft recipients. <i>Transplantation Proceedings</i> , 2001, 33, 3148-3150.	0.6	8
378	Pharmacodynamic monitoring of mycophenolate mofetil in renal allograft recipients. <i>Transplantation Proceedings</i> , 2001, 33, 3313-3315.	0.6	8

#	ARTICLE	IF	CITATIONS
379	Impact of PGE1 on cyclosporine A induced up-regulation of TGF- β 1, its receptors, and related matrix production in cultured mesangial cells. <i>Cytokine</i> , 2003, 22, 189-193.	3.2	8
380	No association between renin-angiotensin system gene polymorphisms and early and long-term allograft dysfunction in kidney transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 2846-2851.	0.7	8
381	Proposal for Guidelines for Publication of Randomized Trials in the American Journal of Transplantation. <i>American Journal of Transplantation</i> , 2005, 5, 644-647.	4.7	8
382	Accumulation of elderly ESRD patients with blood group O on the waiting list. <i>Transplant International</i> , 2011, 24, e83-e84.	1.6	8
383	Desensitization of HLA-Incompatible Kidney Recipients. <i>New England Journal of Medicine</i> , 2011, 365, 1643-1645.	27.0	8
384	Outcome of expanded criteria donor kidneys that were transplanted at other Eurotransplant centers after being rejected by our institution. <i>World Journal of Urology</i> , 2013, 31, 947-952.	2.2	8
385	Treatment With Sirolimus Is Associated With Less Weight Gain After Kidney Transplantation. <i>Transplantation</i> , 2013, 96, 480-486.	1.0	8
386	Anemia Control in Kidney Transplant Recipients Using Once-Monthly Continuous Erythropoietin Receptor Activator: A Prospective, Observational Study. <i>Journal of Transplantation</i> , 2014, 2014, 1-10.	0.5	8
387	Renal Allograft Loss Caused by Cardiorenal Syndrome. <i>Transplantation</i> , 2015, 99, 1208-1215.	1.0	8
388	Donor Genotype and Intragraft Expression of CYP3A5 Reflect the Response to Steroid Treatment During Acute Renal Allograft Rejection. <i>Transplantation</i> , 2017, 101, 2017-2025.	1.0	8
389	<p>Extended Criteria Donors in Living Kidney Transplantation Including Donor Age, Smoking, Hypertension and BMI<p>. <i>Therapeutics and Clinical Risk Management</i> , 2020, Volume 16, 787-793.	2.0	8
390	Obesity, Fat Tissue Parameters, and Arterial Stiffness in Renal Transplant Recipients. <i>Transplantation Proceedings</i> , 2020, 52, 2341-2346.	0.6	8
391	Novel approaches to sarcopenic obesity and weight management before and after kidney transplantation. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, 30, 14-26.	2.0	8
392	Evaluation of severity of delayed graft function in kidney transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 973-981.	0.7	8
393	Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial. <i>Trials</i> , 2022, 23, 270.	1.6	8
394	Rationale for Surrogate Endpoints and Conditional Marketing Authorization of New Therapies for Kidney Transplantation. <i>Transplant International</i> , 0, 35, .	1.6	8
395	FTY720 alters the composition of T-lymphocyte subpopulations in the peripheral blood compartment of renal transplant patients. <i>Transplantation Proceedings</i> , 2002, 34, 2242-2243.	0.6	7
396	Immunohistochemical double-staining of renal allograft tissue: critical assessment of three different protocols. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002, 440, 648-654.	2.8	7

#	ARTICLE	IF	CITATIONS
397	Differential effects of single dose FTY720 on CD62L+ B-cells in stable renal allograft recipients. <i>International Immunopharmacology</i> , 2007, 7, 88-95.	3.8	7
398	Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 283-292.	0.7	7
399	How to Use mTOR Inhibitors? The Search Goes On. <i>American Journal of Transplantation</i> , 2011, 11, 1551-1552.	4.7	7
400	Renal transplantation in the elderly. <i>Transplantation Reviews</i> , 2015, 29, 191-192.	2.9	7
401	Midterm echocardiographic follow-up of cardiac function after living kidney donation. <i>Clinical Nephrology</i> , 2015, 83 (2015), 253-261.	0.7	7
402	Perioperative antibiotic prophylaxis in renal transplantation: a single-center comparison between two regimens and a brief survey among the Eurotransplant renal transplantation centers. <i>World Journal of Urology</i> , 2019, 37, 957-967.	2.2	7
403	Everolimus in de novo kidney transplant recipients participating in the Eurotransplant senior program: Results of a prospective randomized multicenter study (SENATOR). <i>PLoS ONE</i> , 2019, 14, e0222730.	2.5	7
404	A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients. <i>BMC Nephrology</i> , 2019, 20, 36.	1.8	7
405	Anti-interleukin-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism. <i>Transplant International</i> , 2021, 34, 1542-1552.	1.6	7
406	Impact of Early Pancreatic Graft Loss on Outcome after Simultaneous Pancreas-Kidney Transplantation (SPKT) – A Landmark Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 3237.	2.4	7
407	Inosine 5- α -Monophosphate Dehydrogenase Activity for the Longitudinal Monitoring of Mycophenolic Acid Treatment in Kidney Allograft Recipients. <i>Transplantation</i> , 2021, 105, 916-927.	1.0	7
408	A randomized trial of intensified vs. standard dosing for enteric-coated mycophenolate sodium in de novo kidney transplant recipients: results at 1 year. <i>Clinical Nephrology</i> , 2013, 79, 421-431.	0.7	7
409	Treating type 2 diabetes in renal insufficiency: the role of pioglitazone. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2003, 41, 488-491.	0.6	7
410	The immunosuppressive potential of misoprostol – efficacy and variability. <i>Clinical Immunology</i> , 2003, 109, 288-294.	3.2	6
411	Sirolimus Dosage during and after Conversion from Calcineurin Inhibitor Therapy to Sirolimus in Chronic Kidney Transplant Patients. <i>Kidney and Blood Pressure Research</i> , 2004, 27, 186-190.	2.0	6
412	Accurate Prediction of Kidney Allograft Outcome Based on Creatinine Course in the First 6 Months Posttransplant. <i>Transplantation Proceedings</i> , 2005, 37, 731-733.	0.6	6
413	FK506, transforming growth factor- β 1 and mesangial matrix synthesis: Parallels and differences compared with cyclosporine A. <i>Cytokine</i> , 2006, 33, 59-65.	3.2	6
414	Lessons from the CAESAR Study: Calcineurin Inhibitors? Can't Live with Them and Can't Live without Them. <i>American Journal of Transplantation</i> , 2007, 7, 495-496.	4.7	6

#	ARTICLE	IF	CITATIONS
415	Target Enzyme Activity as a Biomarker for Immunosuppression. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 257-260.	2.0	6
416	IMPROVED RENAL FUNCTION OF AN EVEROLIMUS/ENTERIC-COATED MYCOPHENOLATE SODIUM REGIMEN AFTER CALCINEURIN INHIBITOR WITHDRAWAL IN DE NOVO RENAL TRANSPLANT PATIENTS: 2 YEARS FOLLOW-UP OF THE ZEUS TRIAL. <i>Transplantation</i> , 2010, 90, 109.	1.0	6
417	Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS study. <i>Transplant International</i> , 2014, 27, 1192-1204.	1.6	6
418	Target Enzyme Activity and Phosphorylation of Pathway Molecules As Specific Biomarkers in Transplantation. <i>Therapeutic Drug Monitoring</i> , 2016, 38, S43-S49.	2.0	6
419	The selective biomarker IL-8 identifies IFTA after kidney transplantation in blood cells. <i>Transplant Immunology</i> , 2016, 39, 18-24.	1.2	6
420	Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative Recipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Seroconversion and Prevents Cytomegalovirus Disease. <i>Transplantation Proceedings</i> , 2017, 49, 2280-2284.	0.6	6
421	High Incidence of Ovarian Cysts in Women Receiving mTOR Inhibitors After Renal Transplantation. <i>Journal of Women's Health</i> , 2018, 27, 394-398.	3.3	6
422	What happens after graft loss? A large, long-term, single-center observation. <i>Transplant International</i> , 2021, 34, 732-742.	1.6	6
423	Monitoring of gene expression in tacrolimus-treated de novo renal allograft recipients facilitates individualized immunosuppression: Results of the IMAGEN study. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3851-3862.	2.4	6
424	Advantages of plasmatic CXCL-10 as a prognostic and diagnostic biomarker for the risk of rejection and subclinical rejection in kidney transplantation. <i>Clinical Immunology</i> , 2021, 229, 108792.	3.2	6
425	Effect of Concentration/Dose Ratio in De Novo Kidney Transplant Recipients Receiving LCP-Tacrolimus or Immediate-Release Tacrolimus: Post Hoc Analysis of a Phase 3 Clinical Trial. <i>Annals of Transplantation</i> , 2020, 25, e923278.	0.9	6
426	Efficacy and complications of regional citrate anticoagulation during continuous renal replacement therapy in critically ill patients with COVID-19. <i>Journal of Critical Care</i> , 2022, 67, 126-131.	2.2	6
427	Body Mass Index Thresholds and the Use of Bariatric Surgery in the Field of Kidney Transplantation in Germany. <i>Obesity Surgery</i> , 2022, 32, 1641-1648.	2.1	6
428	The mTOR inhibitor Rapamycin protects from premature cellular senescence early after experimental kidney transplantation. <i>PLoS ONE</i> , 2022, 17, e0266319.	2.5	6
429	Proposed Definitions of Antibody-Mediated Rejection for Use as a Clinical Trial Endpoint in Kidney Transplantation. <i>Transplant International</i> , 0, 35, .	1.6	6
430	Cross-over Kidney Transplantation with Simultaneous Laparoscopic Living Donor Nephrectomy: Initial Experience. <i>European Urology</i> , 2008, 53, 1074-1078.	1.9	5
431	Fate of Finally Transplanted Deceased Donor Kidneys Initially Rejected at Other Kidney Transplantation Centers. <i>Urologia Internationalis</i> , 2014, 93, 474-481.	1.3	5
432	Bortezomib-Based Antibody Reduction Therapy: The First Step to "True" Desensitization?. <i>American Journal of Transplantation</i> , 2015, 15, 10-12.	4.7	5

#	ARTICLE	IF	CITATIONS
433	Simultaneous determination of mycophenolate and its metabolite mycophenolate-7-o-glucuronide with an isocratic HPLC-UV-based method in human plasma and stability evaluation. Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, 612-619.	1.2	5
434	Successful Recovery of Acute Renal Transplant Failure in Recurrent Hepatitis C Virus-Associated Membranoproliferative Glomerulonephritis. American Journal of Transplantation, 2017, 17, 819-823.	4.7	5
435	Predictors of graft survival at diagnosis of antibody-mediated renal allograft rejection: a retrospective single-center cohort study. Transplant International, 2020, 33, 149-160.	1.6	5
436	Tomoelastography for Longitudinal Monitoring of Viscoelasticity Changes in the Liver and in Renal Allografts after Direct-Acting Antiviral Treatment in 15 Kidney Transplant Recipients with Chronic HCV Infection. Journal of Clinical Medicine, 2021, 10, 510.	2.4	5
437	Everolimus therapy for angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangiomyomatosis: Results from EXIST-2.. Journal of Clinical Oncology, 2012, 30, 356-356.	1.6	5
438	Development of Graft-Site Candidiasis in 3 Solid Organ Transplant Recipients from the Same Donor. American Journal of Case Reports, 2017, 18, 777-781.	0.8	5
439	Pan-Genotype Pre-Exposure Prophylaxis (PrEP) Allows Transplantation of HCV-Positive Donor Kidneys to Negative Transplant Recipients. Journal of Clinical Medicine, 2021, 10, 89.	2.4	5
440	Outcomes of Deceased Donor Kidney Transplantation in the Eurotransplant Senior Program with A Focus on Recipients ≥75 Years. Journal of Clinical Medicine, 2021, 10, 5633.	2.4	5
441	Mycophenolate mofetil pharmacokinetics in renal transplant recipients on peritoneal dialysis. Transplant International, 1998, 11, 53-57.	1.6	5
442	Initial Experience With SARS-CoV-2-Neutralizing Monoclonal Antibodies in Kidney or Combined Kidney-Pancreas Transplant Recipients. Transplant International, 2022, 35, 10109.	1.6	5
443	Steroid withdrawal in long-term cyclosporine a treated patients using mycophenolate mofetil: a prospective randomized pilot study. Transplantation Proceedings, 2001, 33, 3250-3252.	0.6	4
444	Laparoscopic kidney harvesting for living donor kidney transplantation- one year follow-up of the initial 15 patients. Transplantation Proceedings, 2001, 33, 3791-3792.	0.6	4
445	Successful steroid withdrawal at the end of the 1st year after renal transplantation in mycophenolate mofetil-treated patients. Transplantation Proceedings, 2002, 34, 1700-1702.	0.6	4
446	Five year outcome of tacrolimus rescue therapy in late rejection after renal transplantation. Transplantation Proceedings, 2002, 34, 1594-1596.	0.6	4
447	Enteric-Coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF), it is Better to Have the Choice. American Journal of Transplantation, 2005, 5, 1165-1166.	4.7	4
448	No Evidence for a Relationship Between Infiltrates in Renal Protocol Biopsies and Outcome. American Journal of Transplantation, 2007, 7, 2637-2638.	4.7	4
449	Why Rejections Are Not Biopsy Proven: Frequency and Reasons. Transplantation Proceedings, 2010, 42, 4509-4512.	0.6	4
450	Superior Renal Function in an Everolimus-Based Calcineurin Inhibitor Free Regimen Compared to Standard Cyclosporine/Mycophenolate and Low Cyclosporine/Everolimus: Follow-Up of the HERAKLES Study at Month 36.. Transplantation, 2014, 98, 81.	1.0	4

#	ARTICLE	IF	CITATIONS
451	Human Leukocyte Antigenâ€“Incompatible Kidney Transplantation After â€œDesensitizationâ€œ” Hope and Reality. <i>Transplantation</i> , 2014, 98, 819-820.	1.0	4
452	Current status of immunosuppressive minimization and tolerance strategies. <i>Transplant International</i> , 2015, 28, 889-890.	1.6	4
453	Influence of pretransplant class I and II non-donor-specific anti-HLA immunization on immunologic outcome and graft survival in kidney transplant recipients. <i>Transplant Immunology</i> , 2020, 63, 101333.	1.2	4
454	Is a Retroaortic Vein a Risk Factor in Laparoscopic Living Donor Nephrectomy?. <i>Urologia Internationalis</i> , 2020, 104, 641-645.	1.3	4
455	Intensive monitoring of post filter ionized calcium concentrations during CVVHD with regional citrate anticoagulation: A retrospective study. <i>Journal of Critical Care</i> , 2020, 58, 1-5.	2.2	4
456	The relationship between proteinuria and allograft survival in patients with transplant glomerulopathy: a retrospective singleâ€“center cohort study. <i>Transplant International</i> , 2021, 34, 259-271.	1.6	4
457	Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform. <i>Journal of Visualized Experiments</i> , 2021, , .	0.3	4
458	SUCCESSFUL STEROID WITHDRAWAL DURING THE FIRST YEAR AFTER RENAL TRANSPLANTION IN MYCOPHENOLATE MOFETIL AND CYCLOSPORINE TREATED PATIENTS. <i>Transplantation</i> , 1999, 67, S160.	1.0	4
459	Cyclosporin C2hour monitoring after renal transplantation. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2003, 41, 477-481.	0.6	4
460	Information Extraction Models for German Clinical Text. , 2020, , .		4
461	Kidney Perfusion in Contrast-Enhanced Ultrasound (CEUS) Correlates with Renal Function in Living Kidney Donors. <i>Journal of Clinical Medicine</i> , 2022, 11, 791.	2.4	4
462	Impact of COVID-19 on Global Kidney Transplantation Service Delivery: Interim Report. <i>Transplant International</i> , 2022, 35, 10302.	1.6	4
463	Poor Long-Term Renal Allograft Survival in Patients with Chronic Antibody-Mediated Rejection, Irrespective of Treatmentâ€“A Single Center Retrospective Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 199.	2.4	4
464	Disappearance of hepatitis B virus core deletion mutants and successful combined kidney/liver transplantation in a patient treated with lamivudine. <i>Transplant International</i> , 1999, 12, 283-287.	1.6	4
465	Long-term outcome of tacrolimus rescue therapy in late rejection after renal transplantation. <i>Transplantation Proceedings</i> , 1998, 30, 1780-1781.	0.6	3
466	Profibrotic cytokines and lymphocyte proliferation in stable renal allograft recipients treated with or without cyclosporine A. <i>Clinical Immunology</i> , 2006, 119, 59-66.	3.2	3
467	De novo Renal Transplantation after Kaposi Sarcoma: Favorable Outcome in a Patient Receiving Sirolimus and Mycophenolate-Based Immunosuppression. <i>Case Reports in Dermatology</i> , 2010, 2, 32-35.	0.8	3
468	About Incidence and Timing of Donor-Specific Antibodies After Graft Nephrectomy. <i>Transplantation</i> , 2012, 93, 865-866.	1.0	3

#	ARTICLE	IF	CITATIONS
469	Efficacy and Safety of Three Different Treatment Regimens in de Novo Renal Transplant Patients: Results of the HERAKLES Trial. <i>Transplantation</i> , 2012, 94, 995.	1.0	3
470	Efficacy and Safety of Three Different Treatment Regimens in De Novo Renal Transplant Patients: Month 36 Follow-Up Results of HERAKLES Trial.. <i>Transplantation</i> , 2014, 98, 81-82.	1.0	3
471	Conversion to Belatacept based regimen does not change T-cell phenotype and function in renal transplantation. <i>Transplant Immunology</i> , 2015, 33, 176-184.	1.2	3
472	PD04-03 EVEROLIMUS FOR RENAL ANGIOMYOLIPOMA ASSOCIATED WITH TSC OR SLAM: FINAL LONG-TERM RESULTS FROM EXIST-2. <i>Journal of Urology</i> , 2016, 195, .	0.4	3
473	Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study. <i>BMC Nephrology</i> , 2018, 19, 154.	1.8	3
474	Pharmacokinetics of Daclatasvir, Sofosbuvir, and GS-331007 in a Prospective Cohort of Hepatitis C Virus-Positive Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 53-58.	2.0	3
475	Analysis of Risk Factors and Long-Term Outcomes in Kidney Transplant Patients with Identified Lymphoceles. <i>Journal of Clinical Medicine</i> , 2020, 9, 2841.	2.4	3
476	Should We Perform Old-For-Old Kidney Transplantation during the COVID-19 Pandemic? The Risk for Post-Operative Intensive Stay. <i>Journal of Clinical Medicine</i> , 2020, 9, 1835.	2.4	3
477	Determinants of Successful Use of Sirolimus in Renal Transplant Patients. <i>Transplantation Proceedings</i> , 2020, 52, 3103-3111.	0.6	3
478	Does the Side Matter? A Retrospective Cohort Study Comparing Left and Right Pure Laparoscopic Donor Nephrectomies. <i>Urologia Internationalis</i> , 2021, 105, 1076-1084.	1.3	3
479	A Web-Based Electronic Patient Record System as a Means for Collection of Clinical Data. <i>Lecture Notes in Computer Science</i> , 2001, , 198-205.	1.3	3
480	Poor Outcomes in Patients With Transplant Glomerulopathy Independent of Banff Categorization or Therapeutic Interventions. <i>Frontiers in Medicine</i> , 2022, 9, .	2.6	3
481	Tacrolimus Rescue Therapy in Late Rejection After Renal Transplantation: Outcome After 18 Months. <i>Transplantation Proceedings</i> , 1998, 30, 1238-1239.	0.6	2
482	Late conversion to mycophenolate mofetil for chronic deterioration of renal allograft function. <i>Transplantation Proceedings</i> , 1998, 30, 2229.	0.6	2
483	Long-term investigation of hepatitis G virus infection in renal transplant recipients with and without hepatitis B and C co-infection. <i>Transplantation Proceedings</i> , 1999, 31, 1382-1383.	0.6	2
484	Prostaglandin E1 inhibits cyclosporine A-induced upregulation of transforming growth factor-beta 1 in rat mesangial cells. <i>Transplantation Proceedings</i> , 2001, 33, 3342-3344.	0.6	2
485	Living donor Nephrectomy- No impact of genetic relationship. <i>Transplantation Proceedings</i> , 2003, 35, 2860-2862.	0.6	2
486	Evaluating candidates for kidney transplantation: some recommendations still lack convincing clinical evidence. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 621-622.	0.7	2

#	ARTICLE	IF	CITATIONS
487	IMPACT OF DACLIZUMAB AND LOW DOSE CYCLOSPORINE IN COMBINATION WITH MYCOPHENOLATE MOFETIL AND STEROIDS ON RENAL FUNCTION AFTER KIDNEY TRANSPLANTATION. <i>Transplantation</i> , 2004, 78, 280-281.	1.0	2
488	Immunosuppressive Potential and Side Effects of Everolimus. <i>American Journal of Transplantation</i> , 2012, 12, 2563-2563.	4.7	2
489	Tacrolimus only for breakfast â€¦*. <i>Transplant International</i> , 2012, 25, 274-275.	1.6	2
490	Conversion From Tacrolimus to Cyclosporine A Improves Glucose Metabolism in Patients With New Onset Diabetes After Transplantation: Interim Analysis of a Prospective and Randomized Study.. <i>Transplantation</i> , 2014, 98, 95.	1.0	2
491	PD35-10 EVEROLIMUS FOR RENAL ANGIOMYOLIPOMA ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX: EFFICACY AND SAFETY AFTER 3.5 YEARS OF TREATMENT IN THE EXIST-2 STUDY. <i>Journal of Urology</i> , 2015, 193, .	0.4	2
492	Living Donor Transplantation: Long-Term Evolution Related to Age Matching. <i>Transplantation Proceedings</i> , 2015, 47, 2346-2350.	0.6	2
493	Invited letter in response to â€œPredicted indirectly recognizable HLA epitopes (PIRCHE): Only the tip of the iceberg?â€. <i>American Journal of Transplantation</i> , 2018, 18, 523-524.	4.7	2
494	ANTI-IL-6 ANTIBODY CLAZAKIZUMAB IN LATE ANTIBODY-MEDIATED REJECTION â€œ MOLECULAR REBOUND PHENOMENA UNDER IL-6 BLOCKADE?. <i>Transplantation</i> , 2020, 104, S67-S67.	1.0	2
495	STEADY-STATE PHARMACOKINETICS AND TOLERABILITY OF RAD AND ITS INFLUENCE ON CYCLOSPORINE IN STABLE RENAL TRANSPLANT PATIENTS. <i>Transplantation</i> , 1999, 67, S160.	1.0	2
496	The The renin-angiotensin-aldosterone system blockade and arterial stiffness in renal transplant recipients â€œ a cross-sectional prospective observational clinical study. <i>Acta Biochimica Polonica</i> , 2020, 67, 613-622.	0.5	2
497	Influence of lipid profile and statin administration on arterial stiffness in renal transplant recipients. <i>Cardiology Journal</i> , 2022, 29, 263-271.	1.2	2
498	Pharmacokinetic principles of immunosuppressive drugs. <i>Annals of Transplantation</i> , 2008, 13, 5-10.	0.9	2
499	Case-based reasoning algorithm for kidney transplant monitoring. <i>Transplantation Proceedings</i> , 2001, 33, 3331-3333.	0.6	1
500	Suggested guidelines for reporting clinical results in transplantation trials. <i>Transplantation Reviews</i> , 2007, 21, 136-142.	2.9	1
501	Superior Renal Function in an Everolimus-Based Calcineurin Inhibitor Free Regimen Compared to Standard Cyclosporine/Mycophenolate and Low Cyclosporine/Everolimus: The HERAKLES Study. <i>Transplantation</i> , 2012, 94, 993.	1.0	1
502	Improved Renal Function of an Everolimus/Enteric-Coated Mycophenolate Sodium Regimen after Calcineurin Inhibitor Withdrawal in de Novo Renal Transplant Patients: 4 Years Follow-Up of the ZEUS Trial. <i>Transplantation</i> , 2012, 94, 993.	1.0	1
503	Renal Function of an Everolimus Based Therapy after Calcineurin Inhibitor Withdrawal in Maintenance Renal Transplant Recipients: 3 Year Data of the APOLLO Trial. <i>Transplantation</i> , 2012, 94, 994.	1.0	1
504	Sotrastaurin + Reduced-Exposure Tacrolimus Prevents Acute Rejection and Preserves Renal Function after De Novo Kidney Transplantation - 12 Month Results. <i>Transplantation</i> , 2012, 94, 980.	1.0	1

#	ARTICLE	IF	CITATIONS
505	Three-Year Outcomes in Patients with Delayed Graft Function in Phase III Studies of Belatacept Vs Cyclosporine in Kidney Transplantation (BENEFIT and BENEFIT-EXT). <i>Transplantation</i> , 2012, 94, 996.	1.0	1
506	1302 EXIST-2: EFFECT OF EVEROLIMUS ON ANGIOMYOLIPOMA IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX OR SPORADIC LYMPHANGIOMYOMATOSIS. <i>Journal of Urology</i> , 2012, 187, .	0.4	1
507	Two-Year Results of Envarsus (Once-Daily MeltDose Tacrolimus Tablets) vs Prograf (Twice-Daily) Tj ETQq1 1 0.784314 rgBT /Overlock Study.. <i>Transplantation</i> , 2014, 98, 661-662.	1.0	1
508	Post Hoc Analysis of ZEUS and HERAKLES, Two Prospective, Open-Label, Multicenter, Randomized Trials: Onset and Progression of Diabetes in Kidney Transplant Recipients On Cyclosporine Standard or Converted to CNI-Free or CNI-Low Everolimus Regimen.. <i>Transplantation</i> , 2014, 98, 145-146.	1.0	1
509	PD17-01 EVEROLIMUS FOR RENAL ANGIOMYOLIPOMA ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX: EXIST-2 LONG-TERM EFFICACY AND SAFETY. <i>Journal of Urology</i> , 2014, 191, .	0.4	1
510	Immunologic Long-term Outcomes of Living-Related Kidney Transplantations Depending on the Donor-Recipient Relationship. <i>Transplantation Proceedings</i> , 2017, 49, 2265-2268.	0.6	1
511	Late Steroid Withdrawal Following ABO-Incompatible Renal Transplantation. <i>Transplantation Proceedings</i> , 2018, 50, 72-78.	0.6	1
512	SaO014USE OF A MOBILE APP TO IMPROVE MEDICATION ADHERENCE IN KIDNEY TRANSPLANT RECIPIENTS - A PROSPECTIVE INTERVENTIONAL STUDY. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i321-i321.	0.7	1
513	Kidney graft function and arterial stiffness in renal transplant recipients. <i>Acta Biochimica Polonica</i> , 2021, 68, 331-339.	0.5	1
514	Clinicopathologic Features and Risk Factors of Proteinuria in Transplant Glomerulopathy. <i>Frontiers in Medicine</i> , 2021, 8, 666319.	2.6	1
515	Low-dose rapamycin does not impair vascular integrity and tubular regeneration after kidney transplantation in rats. <i>Scientific Reports</i> , 2021, 11, 16270.	3.3	1
516	Analysis of Factors Affecting Employment Status of Kidney Transplant Recipients in Selected European Union Member States. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 10284.	2.6	1
517	mHealth und digitales Management nach Nierentransplantation. <i>Nieren- Und Hochdruckkrankheiten</i> , 2017, 46, 474-480.	0.0	1
518	Declining Course of Humoral Immune Response in Initially Responding Kidney Transplant Recipients after Repeated SARS-CoV-2 Vaccination. <i>Journal of Clinical Medicine</i> , 2022, 11, 3291.	2.4	1
519	Body composition and substrate oxidation in long-term survivors after transplantation of liver or kidney. <i>Gastroenterology</i> , 1998, 114, A1330.	1.3	0
520	Renal failure from diabetic glomerulosclerosis three decades after allograft transplantation. <i>Nephrology Dialysis Transplantation</i> , 1999, 14, 974-976.	0.7	0
521	PROBLEMS OF CYCLOSPORINE ABSORPTION PROFILING USING C2-MONITORING. <i>Transplantation</i> , 2004, 78, 457.	1.0	0
522	Differences in Reporting of Acute Rejections Between American and European Publications of Large Immunosuppressive Trials Impair Comparability of Study Results. <i>Transplantation Proceedings</i> , 2005, 37, 2048-2050.	0.6	0

#	ARTICLE	IF	CITATIONS
523	RENAL FUNCTION OF AN EVEROLIMUS BASED THERAPY AFTER CALCINEURIN INHIBITOR WITHDRAWAL IN MAINTENANCE RENAL TRANSPLANT RECIPIENTS ONE YEAR AFTER CONVERSION. <i>Transplantation</i> , 2010, 90, 612.	1.0	0
524	AN INTENSIFIED DOSING OF ENTERIC-COATED MYCOPHENOLATE SODIUM IN RENAL TRANSPLANT PATIENTS RESULTS IN IMPROVED EFFICACY WITHOUT COMPROMISING SAFETY: 1 YEAR FOLLOW-UP RESULTS. <i>Transplantation</i> , 2010, 90, 611.	1.0	0
525	Pretransplant PRA and Long-Term Outcomes of Kidney Transplant Recipients. <i>Transplantation</i> , 2012, 94, 1076.	1.0	0
526	Clindamycin-Primaquine Is Safe in Treating Pneumocystis Pneumonia in Renal Transplant Patients but Appears to Be Less Effective than Trimethoprim/Sulfamethoxazole. <i>Transplantation</i> , 2012, 94, 547.	1.0	0
527	The Effect of Acute Rejection Episodes According to Banff 2009 on Long-Term Outcome of Patients after Kidney Transplantation. <i>Transplantation</i> , 2012, 94, 241.	1.0	0
528	Determinants of Outcome after KTX in Elderly Patients. <i>Transplantation</i> , 2012, 94, 922.	1.0	0
529	The Effect of Acute Rejection Episodes According to Banff 2009 on Long-Term Outcome of Patients after Kidney Transplantation. <i>Transplantation</i> , 2012, 94, 1044.	1.0	0
530	Determinants and Duration of Hospitalisations after KTX in Elderly Patients. <i>Transplantation</i> , 2012, 94, 918.	1.0	0
531	A Phase III Randomized Trial of Conversion to Once-Daily Extended Release Melted® Tacrolimus Tablets (LCP-Tacro®, [®]) from Twice-Daily Tacrolimus Capsules (Prograf®): Efficacy Results from an Analysis of Specific Patient Sub-Populations. <i>Transplantation</i> , 2012, 94, 984.	1.0	0
532	Effects of Sotrastaurin, Mycophenolic Acid and Everolimus on Human B-Lymphocyte Function and Activation. <i>Transplantation</i> , 2012, 94, 1117.	1.0	0
533	Pre-Operative Assessment of Living Renal Transplant Donors with State-Of-The-Art Imaging Modalities: Computed Tomography Angiography vs. Magnetic Resonance Angiography in 118 Patients. <i>Transplantation</i> , 2012, 94, 187.	1.0	0
534	IMP-Dehydrogenase in Erythrocytes for Detection of Non-Adherence to MPA Therapy. <i>Transplantation</i> , 2012, 94, 1191.	1.0	0
535	Effect of everolimus, an oral mtor inhibitor, on angiogenic biomarkers in patients with tuberous sclerosis complex (TSC) and skin lesions. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, AB48.	1.2	0
536	Once-Daily Envarsus Demonstrates Comparable Efficacy and Safety to Twice-Daily Prograf: A Phase 3 Study for Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients.. <i>Transplantation</i> , 2014, 98, 116.	1.0	0
537	Rapid Attainment of Tacrolimus Trough Levels Early Post-Transplant Reduces Risk of Treatment Failure in De Novo Kidney Transplant Patients: A Covariate Analysis of a Phase 3 Double-Blind Study.. <i>Transplantation</i> , 2014, 98, 459.	1.0	0
538	FP825IMMUNOLOGIC OUTCOMES IN ELDERLY KIDNEY TRANSPLANT RECIPIENTS. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii352-iii353.	0.7	0
539	FP834IMPACT OF PREGNANCIES ON IMMUNIZATION AND OUTCOME IN KIDNEY TRANSPLANTATION. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii356-iii356.	0.7	0
540	FP837BODY MASS INDEX (BMI) MISMATCH IN DECEASED KIDNEY DONATION IS AN INDEPENDENT RISK FACTOR FOR GRAFT FAILURE. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii357-iii357.	0.7	0

#	ARTICLE	IF	CITATIONS
541	FP870HLA-DR MATCHING IMPROVES IMMUNOLOGIC OUTCOMES IN ELDERLY KIDNEY TRANSPLANT RECIPIENTS. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii367-iii368.	0.7	0
542	Effect of everolimus on polycystic liver volume in autosomal dominant polycystic kidney disease. <i>Clinical and Experimental Nephrology</i> , 2015, 19, 757-758.	1.6	0
543	Effect of everolimus on skin lesions in patients being treated for subependymal giant cell astrocytoma and renal angiomyolipoma: Final 4-year results from EXIST-1 and EXIST-2. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, AB127.	1.2	0
544	Psychosocial Long-Term Impact of Donation on Kidney Living Donors - A Comparative Study of Two Major European Transplant Centres. <i>Transplantation</i> , 2018, 102, S612.	1.0	0
545	FP713DE NOVO MALIGNANCIES AFTER KIDNEY TRANSPLANTATION: A LONG-TERM OBSERVATIONAL STUDY. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i286-i286.	0.7	0
546	Risks and benefits of everolimus. <i>Transplant International</i> , 2019, 32, 1124-1126.	1.6	0
547	P0821OBESITY, FAT TISSUE, CELL MEMBRANE INTEGRITY PARAMETERS AND ARTERIAL STIFFNESS IN RENAL TRANSPLANT RECIPIENTS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
548	ANALYZING CAUSES FOR DEATH-CENSORED ALLOGRAFT FAILURE IN KIDNEY TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 2020, 104, S69-S70.	1.0	0
549	STABIL-study: The Course of Therapy, Safety and Pharmacokinetic Parameters of Conversion of Prograf® to Tacrolimus HEXAL®/Crilomus® in Renal Transplant Recipients – An Observational Study in Germany. <i>Current Clinical Pharmacology</i> , 2021, 16, 357-368.	0.6	0
550	MO938PATIENT SURVIVAL AFTER LIVING DONOR KIDNEY DONATION. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0
551	MO105TELEMEDICAL SURVEILLANCE AND OPTIMIZED TREATMENT OF BLOOD PRESSURE IN KIDNEY TRANSPLANT RECIPIENTS. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0
552	MO943IMPACT OF NON-ACTIVE HEPATITIS B ON PATIENT SURVIVAL AFTER RENAL TRANSPLANTATION. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0
553	Effectiveness of interventions in patients who develop graft nephrolithiasis after kidney transplantation: A systematic review. <i>European Urology</i> , 2021, 79, S466-S467.	1.9	0
554	Cytosorb® Rescue for COVID-19 Patients with Vasoplegic Shock (CytoResc): A Prospective, Open-Label, Randomised Controlled Pilot Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
555	Aktuelle Aspekte der Immunsuppression nach Nierentransplantation. <i>Nieren- Und Hochdruckkrankheiten</i> , 2008, 37, 602-613.	0.0	0
556	Post-Transplantations-Diabetes mellitus nach Nierentransplantation. <i>Nieren- Und Hochdruckkrankheiten</i> , 2013, 42, 532-538.	0.0	0
557	Intensivierte vs. standardmäßige Dosierung von magensaftresistentem Mycophenolat- Natrium bei De-novo-Nierentransplantatempfängern: 1-Jahres-Ergebnisse einer randomisierten Studie. <i>Nieren- Und Hochdruckkrankheiten</i> , 2014, 43, 297-309.	0.0	0
558	Echokardiografische Evaluation von Veränderungen der kardialen Struktur und Funktion nach Lebendnierenspende. <i>Nieren- Und Hochdruckkrankheiten</i> , 2015, 44, 501-510.	0.0	0

#	ARTICLE	IF	CITATIONS
559	Nierenfunktion, Wirksamkeit und Sicherheit nach spÄter Umstellung von Calcineurininhibitoren auf Everolimus bei Patienten nach Nierentransplantation: die randomisierte APOLLO-Studie. Nieren- Und Hochdruckkrankheiten, 2016, 45, 145-156.	0.0	0
560	FrÃ¼he Umstellung von Cyclosporin auf Everolimus nach Lebendnierentransplantation: 5 Jahresdaten der randomisierten ZEUS Studie. Nieren- Und Hochdruckkrankheiten, 2017, 46, 105-117.	0.0	0
561	Barriers to online consultation in nephrological care: An online-survey among nephrologists. Clinical Nephrology, 2022, 97, 129-130.	0.7	0
562	IMPACT OF NON-ACTIVE HEPATITIS B ON PATIENT SURVIVAL AFTER RENAL TRANSPLANTATION. Transplantation, 2020, 104, S314-S315.	1.0	0
563	NT-PRO BNP, VISCERAL FAT AREA, CELL MEMBRANE INTEGRITY AND ARTERIAL STIFFNESS IN RENAL TRANSPLANT RECIPIENTS. Transplantation, 2020, 104, S600-S600.	1.0	0
564	THREE-MONTH RESULTS OF A PHASE 2 TRIAL EVALUATING CLAZAKIZUMAB IN LATE ANTIBODY-MEDIATED REJECTION " EARLY IMPACT OF IL-6 BLOCKADE ON DONOR-SPECIFIC ANTIBODY LEVELS, REJECTION MORPHOLOGY AND GENE EXPRESSION. Transplantation, 2020, 104, S355-S355.	1.0	0
565	Authorsâ€™ Reply: SARS-CoV-2 Vaccination in Kidney Transplant Recipients: Should We Consider Intradermal Vaccination?. Journal of the American Society of Nephrology: JASN, 2022, 33, 870-871.	6.1	0
566	Influence of Belatacept- vs. CNI-Based Immunosuppression on Vascular Stiffness and Body Composition. Journal of Clinical Medicine, 2022, 11, 1219.	2.4	0